Pharmaceuticals Europe

Europe Antifungal Drugs Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Europe Antifungal Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Infection, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $2.68 Bn Placeholder estimate
Estimate 2025 $2.74 Bn 17.1% of the global market
Projected 2034 $3.40 Bn 23.8% Adds $653.0 Mn over 9 forecast years
CAGR 2025–2034 2.4% Faster than 4% of 186 Pharmaceuticals markets here
Key players 5
  • Europe is 17.08% of the global market.
  • Among regions, the largest is North America at $7.51 Bn.
  • Fastest growing: Africa at 5% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$653.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Antifungal Drugs Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $2.68 Bn — —
2025 (base) $2.74 Bn +$64.3 Mn —
2026 (forecast) $2.81 Bn +$65.9 Mn +2.4%
2027 (forecast) $2.88 Bn +$67.4 Mn +4.9%
2028 (forecast) $2.95 Bn +$69.1 Mn +7.4%
2029 (forecast) $3.02 Bn +$70.7 Mn +10%
2030 (forecast) $3.09 Bn +$72.4 Mn +12.6%
2031 (forecast) $3.16 Bn +$74.2 Mn +15.3%
2032 (forecast) $3.24 Bn +$75.9 Mn +18.1%
2033 (forecast) $3.32 Bn +$77.8 Mn +20.9%
2034 (forecast) $3.40 Bn +$79.6 Mn +23.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Antifungal Drugs Market Analysis at a glance
Market size, 2025$2.74 Bn placeholder estimate
Forecast, 2034$3.40 Bn placeholder estimate
Growth (CAGR), 2025–20342.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, infection and end user (see all)
Key playersPfizer Inc., Astellas Pharma Inc., Merck & Co., Inc., Mundipharma, Basilea Pharmaceutica (see all)
Regulator in EuropeEMASource: European Medicines Agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Antifungal Drugs Market Analysis Executive Summary

Antifungal drugs treat infections caused by fungi, from skin and nail infections to life-threatening infections in hospital patients.

Key segments of the antifungal Drugs market include drug class (Azoles, Echinocandins and Polyenes) and infection (Superficial and Invasive).

Bar chart: Europe Antifungal Drugs market size, 2024–2034, placeholder estimates. $2.68 Bn in 2024, $2.74 Bn in 2025 and $3.40 Bn in 2034, 2.4% CAGR.
Europe Antifungal Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Antifungal Drugs Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the antifungal Drugs market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the antifungal Drugs market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the antifungal Drugs market.

Competitive Landscape for Antifungal Drugs Market in Europe

The antifungal Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Antifungal Drugs Market in Europe

Antifungal Drugs in Europe: rules and payment

In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).⁠[1] In the countries we cover here, medicines are approved by ANSM (France)⁠[2], BfArM (Germany)⁠[3], AIFA (Italy)⁠[4], Ministry of Health (Russia)⁠[5], AEMPS (Spain)⁠[6], MHRA (UK)⁠[7], CBG-MEB (Netherlands)⁠[8], FAMHP (Belgium)⁠[9], Swissmedic (Switzerland)⁠[10], Läkemedelsverket (Sweden)⁠[11], Danish Medicines Agency (Denmark)⁠[12], URPL (Poland)⁠[13] and TITCK (Turkey)⁠[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[15]

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for antifungal Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Antifungal Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Antifungal Drugs in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Antifungal Drugs market in Europe?
Placeholder estimate: about $2.74 Bn in 2025, rising to about $3.40 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Antifungal Drugs market in Europe growing?
Placeholder estimate: about 2.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Antifungal Drugs market report cover?
The report splits the market by drug class (Azoles, Echinocandins, Polyenes, Allylamines), infection (Superficial, Invasive) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Antifungal Drugs market?
Key players include Pfizer Inc., Astellas Pharma Inc., Merck & Co., Inc., Mundipharma and Basilea Pharmaceutica.
What is driving the Antifungal Drugs market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the antifungal Drugs market.
Who regulates Antifungal Drugs in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How much research is published on Antifungal Drugs?
PubMed lists 2,372 papers on Antifungal Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Europe

See all

Related on infectious diseases and skin and hair

See the topic